storage stability comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
87Rb, 187Re, 176Lu, 232Th, and 238U have half-lives long enough that their decay is limited over geological time scales; 40K and 235U have shorter half-lives and are hence severely depleted, but are still long-lived enough to remain present in significant amount on Earth. The longest-lived isotope not proven to be primordial is 146Sm, which has a half-life of 9.20×107 years, followed by 244Pu (8.13×107 years) and 92Nb (3.47×107 years). 244Pu was reported to exist in nature as a primordial nuclide in 1971, but this detection could not be confirmed by further studies in 2012 and 2022. Taking into account that all these nuclides must exist for at least 4.58×109 years, 146Sm must survive 50 half-lives (and hence be reduced by 250 ≈ 1×1015), 244Pu must survive 57 (and be reduced by a factor of 257 ≈ 1×1017), and 92Nb must survive 130 (and be reduced by 2130 ≈ 1×1039). Mathematically, considering the likely initial abundances of these nuclides, primordial 146Sm and 244Pu should persist somewhere within the Earth today, even if they are not identifiable in the relatively minor portion of the Earth's crust available to human assays, while 92Nb and all shorter-lived nuclides should not. Nuclides such as 92Nb that were present in the primordial solar nebula but have long since decayed away completely are termed extinct radionuclides if they have no other means of being regenerated. As for 244Pu, calculations suggest that as of 2022, sensitivity limits were about one order of magnitude away from detecting it as a primordial nuclide.
The stage was also an important part of Thomas's life from 1929 to 1934, as an actor, writer, producer and set painter. He took part in productions at Swansea Grammar School, and with the YMCA Junior Players and the Little Theatre, which was based in the Mumbles. It was also a touring company that took part in drama competitions and festivals around South Wales. Between October 1933 and March 1934, for example, Thomas and his fellow actors took part in five productions at the Mumbles theatre, as well as nine touring performances. Thomas continued with acting and production throughout his life, including his time in Laugharne, South Leigh and London (in the theatre and on radio), as well as taking part in nine stage readings of Under Milk Wood. The Shakespearian actor, John Laurie, who had worked with Thomas on both the stage and radio thought that Thomas would "have loved to have been an actor" and, had he chosen to do so, would have been "Our first real poet-dramatist since Shakespeare." Painting the sets at the Little Theatre was just one aspect of the young Thomas's interest in art. His own drawings and paintings hung in his bedroom in Cwmdonkin Drive, and his early letters reveal a broader interest in art and art theory. Thomas saw writing a poem as an act of construction "as a sculptor works at stone," later advising a student "to treat words as a craftsman does his wood or stone...hew, carve, mould, coil, polish and plane them..." Throughout his life, his friends included artists, both in Swansea and in London, as well as in America.
== History == The company was founded in Bremen on 24 October 1923 as Bremer Flugzeugbau AG by Prof. Henrich Focke, Georg Wulf and Dr. rer. pol. Werner Naumann. Almost immediately, they renamed the company Focke-Wulf Flugzeugbau AG (later Focke-Wulf Flugzeugbau GmbH). Focke-Wulf merged, under government pressure, with Albatros Flugzeugwerke of Berlin in 1931. The Albatros Flugzeugwerke engineer and test pilot Kurt Tank became head of the technical department and started work on the Fw 44 Stieglitz (Goldfinch). Dr Ludwig Roselius became chairman in 1925 and handed over to his brother Friedrich in early 1933. In 1938 Roselius' HAG combine increased its shareholding to 46% and C. Lorenz AG secured 28%. The company was reconstituted as Focke-Wulf Flugzeugbau GmbH and no longer had to publish its accounts. A substantial capital injection occurred at this time. In August 1933 Hans Holle and Rudolf Schubert were given power of attorney over the Berlin branch of Focke-Wulf. Then in October 1933, Focke-Wulf Flugzeugbau A.G. Albatros Berlin was officially registered with the Department of Trade. Dr Roselius always remained the driving force of Focke-Wulf. He and his closest collaborator, Barbara Goette, often met with technical director Professor Kurt Tank. When Roselius died in May 1943, Heinrich Puvogel (later chair of Focke-Wulf) raised 4 million RM and continued handling the financial affairs of Focke-Wulf as chief of Seehandel A.G. Hanna Reitsch demonstrated the Focke-Wulf Fw 61, the first fully controllable helicopter (as opposed to autogyro), in Berlin in 1938.
== Drugs withdrawn == The following therapeutic drugs were withdrawn from the market primarily because of hepatotoxicity: Troglitazone, bromfenac, trovafloxacin, ebrotidine, nimesulide, nefazodone, ximelagatran and pemoline.
Sources: en.wikipedia.org
==== COVID-19 ==== Dogs have been trained to sniff SARS CoV-2-related VOCs since the outbreak of COVID-19 pandemic. Their overall success rates of detection were similar to or higher than reverse transcription polymerase chain reaction (RT-PCR) and antigen testing procedures. Grandjean et al. trained the dogs to sit in front of samples from COVID-19 positive patients. The success rate of distinguishing the sweat odor of individuals with COVID-19 from individuals without COVID-19 was between 83% and 100%. In principle, the dogs could be used to screen individuals with various stages of COVID-19 infections (including asymptotic, presymptomatic individuals with mild to severe symptoms) in different settings such as schools, transportation centers like airports, hospitals, and public gatherings. An advantage of using trained dogs compared to primates or cats to detect COVID-19 is that dogs are animal species with a low risk of binding between ACE2 receptor and SARS CoV-2, making them less likely to be transmitters. To further minimize the risk of transmission to dogs, sniffing sweat (which has low transmission property) is deemed the ideal mechanism for dogs to detect COVID-19. Other advantages of using dogs for screening COVID-19 over the current RT-PCR method are lower cost, decreased intrusiveness to the subjects, and no delay in reporting the results.
Prolonged exposure to dry ice can cause severe skin damage through frostbite, and the fog produced may also hinder attempts to withdraw from contact in a safe manner. Because it sublimes into large quantities of carbon dioxide gas, which could pose a danger of hypercapnia, dry ice should only be exposed to open air in a well-ventilated environment. For this reason, in the context of laboratory safety dry ice is assigned label precaution P403: "Store in a well-ventilated place." Industrial dry ice may contain contaminants that make it unsafe for direct contact with food. Tiny dry ice pellets used in dry ice blast cleaning do not contain oily residues. Dry ice is assigned a UN number, a code for hazardous substances: UN 1845. Dry ice is not classified as a dangerous substance by the European Union, or as a hazardous material by the United States Department of Transportation for ground transportation. However, in the US, it is regulated as a dangerous good when shipped by air or water. International Air Transport Association (IATA) regulations require specific diamond-shaped black-and white labelling to be placed on the package. The package must have adequate ventilation so that it will not rupture from pressure in the event that the Dry Ice begins to sublime in the packaging. The Federal Aviation Administration in the US allows airline passengers to carry up to 2.5 kg (5.5 lb) per person either as checked baggage or carry-on baggage, when used to refrigerate perishables.
This variation is often found in Purwokerto. The word mendoan originates in the Banyumas regional dialect, and means 'flash-fried'. The tempeh is first dipped in spiced flour before quickly frying in very hot oil, resulting in a product that is cooked on the outside, but raw or only partially so on the inside. It has a limp, soft texture compared to the more common, crisp, fully fried tempeh.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.